AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...
Shares in AnaptysBio, a San Diego-based biotech focused on delivering innovative immunology therapeutics, was trading 19% ...
Its most advanced project is MB272, an agonist of B- and T-lymphocyte attenuator (BTLA) which recently started phase 1 testing, and it has a PD-1 agonist called MB151 in late preclinical development.
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback